Prediction: 1 New Reason Eli Lilly Stock Could Still Be Headed Higher

Eli Lilly’s Q1 2026 results reset the story: revenue rose 55.5% YoY to $19.80B and non-GAAP EPS of $8.55 beat by 25.9%, while management lifted full-year revenue guidance to $82.0–$85.0B and EPS to $35.50–$37.00. The article’s 24/7 Wall St. $1,336.12 price target implies 12.41% upside, with the bull case hinging on Foundayo/Orforglipron as a potentially differentiated GLP-1 pill and a broader pipeline. Offsetting risks include a 13% realized price decline (rebates and Zepbound cash-pay cuts) and $584M in acquired IPR&D plus $279M of litigation-related charges.

Analysis

LLY still screens as a quality-growth compounder, but the market is now paying for more than volume growth: it is underwriting that the company can convert category leadership into sustained pricing power. The near-term risk is that the next leg of growth comes with a worse mix, because broader access, cash-pay resets, and ex-U.S. price harmonization tend to dilute margin before they expand total scripts. That means the stock can keep working on guide raises, but the multiple is more vulnerable to any sign that incremental revenue is coming from lower-net-realization channels.

The bigger second-order read-through is competitive, not just company-specific. NVO is forced into a defensive posture: if oral convenience materially lowers adherence friction, the battle shifts from molecule quality to distribution, payer contracting, and dose escalation economics. That is a slower-moving fight than the market usually prices; the first reaction is sentiment-driven, but the 1-3 month catalyst path depends on whether payers actually expand coverage and whether Lilly can scale supply without another price concession cycle.

The contrarian view is that expectations may already assume near-flawless execution on both launch cadence and manufacturing. If realized pricing continues to erode in the low-teens or 2026 EPS drifts toward the low end of guidance, the stock can de-rate quickly even with strong unit growth. On the other hand, if the oral program meaningfully broadens the prescriber base, the upside is less about this quarter’s numbers and more about a 6-18 month TAM expansion that supports premium durability.

Key Decisions for Investors

• Maintain a tactical long LLY bias for 1-3 months, but prefer adding on weakness rather than chasing strength; the trade works if the market keeps rewarding raised guidance and launch momentum, and breaks if 2026 EPS is guided below $35.50.
• Pair trade: long LLY / short NVO over the next 3-6 months to express relative execution and product-cycle divergence; the thesis fails if NVO stabilizes pricing faster than expected or if Lilly’s net price compression accelerates materially.
• Set an alert on LLY realized price trends and gross margin commentary into the next print; if net pricing deterioration widens beyond the current low-teens pace, reduce exposure because revenue growth will not fully translate into earnings power.
• For investors already long the name, consider call-spread structures rather than outright stock to capture the rerating path while capping downside if launch enthusiasm outruns payer adoption.
• Watch for any biosimilar/tariff policy headline as a sector-wide de-rating catalyst; if pharma policy risk becomes explicit, rotate out of high-multiple healthcare growth into lower-duration pharma cash flow names.